Open access
Open access
Powered by Google Translator Translator

Oncology – Breast

RCT: Effect of Denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy in patients with primary breast cancer.

25 May, 2022 | 10:54h | UTC

Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 

RCT: Elacestrant (oral selective estrogen receptor degrader) vs. standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer.

20 May, 2022 | 10:55h | UTC

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial – Journal of Clinical Oncology

Commentary: EMERALD Trial: Oral Selective Estrogen Receptor Degrader as Second- or Third-Line Therapy for Advanced Breast Cancer – The ASCO Post

 

Mammographic breast density, benign breast disease, and subsequent breast cancer risk in 3.9 million Korean women.

19 May, 2022 | 10:51h | UTC

Mammographic Breast Density, Benign Breast Disease, and Subsequent Breast Cancer Risk in 3.9 Million Korean Women – Radiology

News Release: Density, benign disease raise risk of breast cancer – Radiological Society of North America

 

Hair safe study: Effects of scalp cooling on hair preservation and hair regrowth in breast cancer patients receiving chemotherapy – A prospective interventional study.

19 May, 2022 | 10:15h | UTC

Hair safe study: Effects of scalp cooling on hair preservation and hair regrowth in breast cancer patients receiving chemotherapy – A prospective interventional study – The Breast

 

Nonrandomized Controlled Trial: Clinical impact of intraoperative margin assessment in breast-conserving surgery with a novel Pegulicianine Fluorescence–guided system.

18 May, 2022 | 10:28h | UTC

Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence–Guided System: A Nonrandomized Controlled Trial – JAMA Surgery

 

Commentary on Twitter

 

M-A: Electronic health interventions for patients with breast cancer.

16 May, 2022 | 01:16h | UTC

Electronic Health Interventions for Patients With Breast Cancer: Systematic Review and Meta-Analyses – Journal of Clinical Oncology

 

RCT: Treatment with Etirinotecan pegol for patients with metastatic breast cancer and brain metastases.

13 May, 2022 | 10:51h | UTC

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial – JAMA Oncology (free for a limited period)

 

Commentary on Twitter

 

Retrospective Cohort Study: Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer.

9 May, 2022 | 01:40h | UTC

Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer: multicentre study – British Journal of Cancer

 

Commentary on Twitter

 

A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles.

6 May, 2022 | 10:52h | UTC

A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles – Breast Cancer Research and Treatment

 

Recommendations for breast cancer screening in women with extremely dense breasts.

4 May, 2022 | 08:11h | UTC

Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI) – European Radiology

 

RCT: Digital breast tomosynthesis plus synthesized mammography versus digital screening mammography for the detection of invasive breast cancer.

1 May, 2022 | 23:14h | UTC

Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Breast Cancer Screening With Digital Breast Tomosynthesis Plus Synthesized Mammography vs Digital Mammography – The ASCO Post

 

Guideline: Clinical utility of multigene profiling assays in early-stage invasive breast cancer.

1 May, 2022 | 23:06h | UTC

Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline – Current Oncology

 

Endocrine therapy response and 21-Gene expression assay for therapy guidance in HR+/HER2– early breast cancer.

27 Apr, 2022 | 07:41h | UTC

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)

Editorial: Testing Endocrine Response for Managing Primary Estrogen Receptor–Positive Breast Cancer – Journal of Clinical Oncology

Commentary: Gene Score, Endocrine Response Can Guide Early Breast Cancer Therapy – MedPage Today (free registration required)

 

ASCO Guideline Update: biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer.

20 Apr, 2022 | 09:47h | UTC

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update – Journal of Clinical Oncology

 

ASCO Guideline Update: Use of immune checkpoint inhibitor Pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer.

19 Apr, 2022 | 01:18h | UTC

Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology

 

Endocrine therapies for breast and prostate cancers: Essentials for primary care.

19 Apr, 2022 | 01:14h | UTC

Endocrine therapies for breast and prostate cancers: Essentials for primary care – Canadian Family Physician

 

Phase 2 RCT: De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer.

18 Apr, 2022 | 09:31h | UTC

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Evaluation of information theoretic network meta-analysis to rank first-line anticancer regimens for hormone receptor–positive, ERBB2-negative metastatic breast cancer.

14 Apr, 2022 | 07:48h | UTC

Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer – JAMA Network Open

Invited Commentary: Navigating Systemic Therapeutic Options for First-Line Metastatic Hormone Receptor–Positive, ERBB2-Negative Breast Cancer Treatment – JAMA Network Open

 

Study identifies which treatments are associated with an increased risk of heart disease among women with breast cancer.

13 Apr, 2022 | 10:00h | UTC

Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Major study links breast cancer treatment with increased risk of cardiovascular disease – Fred Hutch

 

Commentary on Twitter

 

M-A: Sentinel lymph node biopsy in patients with ductal carcinoma in situ.

11 Apr, 2022 | 00:46h | UTC

Sentinel lymph node biopsy in patients with ductal carcinoma in situ: systematic review and meta-analysis – BJS Open

 

Commentary on Twitter

 

Internal mammary node irradiation in patients with node-positive early breast cancer: fifteen-year results from the Danish breast cancer group internal mammary node study.

11 Apr, 2022 | 00:41h | UTC

Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study – Journal of Clinical Oncology (link to abstract – $ for full-text)

 

Commentary from the author on Twitter (thread – click for more)

 

Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy.

8 Apr, 2022 | 09:43h | UTC

Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy – The Breast

 

Cohort study: Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)adjuvant systemic therapy.

7 Apr, 2022 | 08:09h | UTC

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy – Journal of Clinical Oncology

 

Commentary on Twitter

 

M-A of randomized trials: Effects of capecitabine as part of neo-/adjuvant chemotherapy in patients with breast cancer.

5 Apr, 2022 | 08:06h | UTC

Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients – European Journal of Cancer (link to abstract – $ for full-text)

 

Study Commentary: Older women with breast cancer chose less aggressive treatment when they used a decision aid.

1 Apr, 2022 | 08:16h | UTC

Older women with breast cancer chose less aggressive treatment when they used a decision aid – National Institute for Health Research

Original Study: Bridging the age gap in breast cancer: cluster randomized trial of two decision support interventions for older women with operable breast cancer on quality of life, survival, decision quality, and treatment choices – British Journal of Surgery

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.